Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
Author(s): Michael R Zile Added: 1 year ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had… View more

Heart Failure
AFSymposium 24: Long-Term Effects of PFA on Coronary Arteries
Author(s): Yury Malyshev Added: 1 year ago
AF Symposium 24 — Dr Yury Malyshev (Mount Sinai Hospital, US) joins us to discuss the findings from three studies focusing on the long-term effects of pulsed-field ablation (PFA) on coronary arteries.QuestionsWhat is known currently about the effect of PFA in Coronary Arteries? What is the importance of this topic?What was the study design and cohort?What are the key findings?Who are the take… View more

Electrophysiology & Arrhythmia
EASD 24: Effectiveness of Empagliflozin and GLP1s
Author(s): Phyo Htoo Added: 1 year ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ESC 25: SWEDEPAD 1 and 2
Author(s): Marten Falkenberg , Joakim Nordanstig Added: 3 months ago
ESC Congress 2025 - Paclitaxel-coated devices in critical limb threatening ischemia were not effective in preventing amputation, nor improving quality-of-life in intermittent claudication.Dr Mårten Falkenberg (Sahlgrenska University Hospital, Gothenburg, SE) and Prof Joakim Nordanstig (Sahlgrenska University Hospital, Gothenburg, SE) join us to discuss findings from the SWEDEPAD 1 and 2 parallel… View more

Intervention

Vascular Disease and Surgery
TCT 24: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty
Author(s): Ulf Teichgräber Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of the trial shows that percutaneous transluminal angioplasty (PTA) with the sirolimus drug coated balloon (DCB) in patients with femoropopliteal artery disease was/was not noninferior to PTA with the paclitaxel DCB.Prof Ulf Teichgräber joins us onsite at TCT Conference to discuss the findings from the sirolimus- vs. paclitaxel-coated balloon… View more

Intervention

Vascular Disease and Surgery
Caitlin White
Job title: Assistant Professor of Clinical Medicine
HFSA 25: Excercise Effects of Aficamten Vs Metoprolol in MAPLE-HCM
Author(s): Gregory Lewis Added: 1 month ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance… View more

Heart Failure
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 2 years ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
Job title: Chairman
Research Area(s) / Expertise: Job title: Interventional Cardiologist and Director of Coronary Care and Cardiovascular Research